间充质干细胞改善实体器官移植效果的临床研究  

Mesenchymal stem cells to improve solid organ transplant outcome: clinical trials

作　　者：谭建明[1] 王萍[1] Tan Jianming Wang Ping.(Fujian Provincial Key Laboratory of Transplant Biology, Fuzhou General Hospital of Nanjing Military Command, Fuzhou 350025, Chin)

机构地区：[1]南京军区福州总医院全军器官移植研究所,福州350025

出　　处：《中华细胞与干细胞杂志（电子版）》2016年第5期263-269,共7页Chinese Journal of Cell and Stem Cell（Electronic Edition）

基　　金：国家自然科学基金(81370948);全军"十二五"重点项目(BWS11J004);福建省科技重大专项(2012YZ0001)

摘　　要：综述在临床实体器官移植(SOT)中使用间充质干细胞(MSC)的临床试验结果和研究进展。现己发现从人体不同组织中获得的MSC均有组织修复与免疫调节的功能。以MSC为基础的治疗方法旨在减少缺血-再灌注性损伤和促进免疫耐受。目前的临床研究结果显示:在SOT中使用自体或异体MSC是安全有效地。整体而言,活体亲属肾移植受者使用MSC与改善移植后肾功能、减少排斥反应等密切相关,并可替代免疫诱导和降低免疫抑制剂用量。目前己完成的改善SOT预后的临床试验以评估包括使用MSC的细胞治疗方法的安全性、可行性和有效性。结果支持基于MSC的细胞治疗具有安全性并证实可改善移植后近期疗效。We review the recent progress on the clinical use of mesenehymal stem cells （MSC） in solid organ transplantation（SOT）. Tissue repairing and immunomodulatory properties have been well recognized for MSC obtained from different human tissues. MSC-based therapy has been proposed to reduce ischemia-reperfusion injury and to promote immune tolerance. The results of recent clinical trial support the safety and promising effects of autologous and allogeneic MSC in SOT. Collectively, the use of MSC in recipients of living donor kidney transplantation （LDKT） is associated with improved graft function and reduced rejection. Dose of maintenance immunosuppressants can also be rdueed. The results of the initial clinical trials support the safety of MSC-based therapy and justifying cautious optimism for the immediate future.

关 键 词：间质干细胞 器官移植 组织疗法 临床试验 

分 类 号：R617[医药卫生—外科学]